Asunto(s)
Presión Sanguínea/fisiología , Colesterol/metabolismo , Ejercicio Físico/fisiología , Promoción de la Salud/métodos , Salud del Hombre , Fútbol , Adulto , Dieta Mediterránea , Humanos , Estilo de Vida , Masculino , Persona de Mediana Edad , Proyectos Piloto , Escocia , Pérdida de Peso/fisiologíaRESUMEN
OBJECTIVES: To explore patients views of the management of medication of chronic heart failure (CHF); to explore in what circumstances they have difficulties in managing medication. DESIGN: Qualitative analysis of in-depth interviews using a constant comparative approach. PARTICIPANTS: Patients attending an outpatients clinic with a primary diagnosis of CHF due to left ventricular systolic dysfunction, NYHA Class II or III symptoms, and a history of hospital admission for heart failure. RESULTS: 50 patients were recruited, average age 67.1 years with ranges between 41 and 80 years. 26 were classified as NYHA Class II and 24 Class III. Patients reported developing routines and back up strategies to help with the complex task of medication-taking. They also described circumstances in which they were more likely not to take medication. CONCLUSIONS: This study demonstrates, with a large sample of respondents, the complexities of medication-taking and the difficulties of maintaining constant medication over a long period of time. The study provides examples of patients' strategies for so doing. Health care professionals should recognise that concordance may vary but explore ways in which they can help patients establish routines.
Asunto(s)
Insuficiencia Cardíaca/tratamiento farmacológico , Cooperación del Paciente , Adulto , Anciano , Femenino , Conocimientos, Actitudes y Práctica en Salud , Humanos , Masculino , Persona de Mediana Edad , Investigación Cualitativa , AutoadministraciónRESUMEN
BACKGROUND AND AIMS: We wanted to determine the prevalence of atrial fibrillation (AF) in a community based cross sectional study in greater Glasgow and how current anti-thrombotic management compares to published guidelines. METHODS: 1466 patients with AF were identified in General Practices in our community and 1008 consented to take part. Their demographic details and medical history were recorded. RESULTS: 1466 patients (mean age 73.4; 55% female) with AF were identified, in our community, giving a prevalence of 1%. 53% of patients were on warfarin therapy. Of those not receiving warfarin, only one third had a putative contra-indication. The proportion ofAF patients on warfarin increased with increasing stroke risk, and over the period of the study. CONCLUSIONS: Prevalence of AF was in keeping with previous estimates. The proportion of patients with AF receiving warfarin therapy appears to be increasing. In the moderate risk group, there was a tendency to use more warfarin in the younger age groups compared to the elderly. It was in the moderate and low risk groups that there was still evidence of deviation from published guidelines.
Asunto(s)
Fibrilación Atrial/terapia , Pautas de la Práctica en Medicina , Anciano , Anticoagulantes/uso terapéutico , Fibrilación Atrial/epidemiología , Femenino , Adhesión a Directriz , Humanos , Masculino , Guías de Práctica Clínica como Asunto , Prevalencia , Factores de Riesgo , Escocia/epidemiología , Warfarina/uso terapéuticoRESUMEN
BACKGROUND: Chronic stable angina is a common condition, but considerable differences exist in the likelihood of acute coronary events such as CHD death, non-fatal myocardial infarction (MI) and unstable angina between individual patients. Effective risk prediction is necessary for optimum management. The aim of this study was to identify clinical features and non-invasive test parameters associated with high risk of these coronary events in stable angina and compose a clinically useful model to predict adverse outcomes in this population. METHODS: Six hundred and eighty-two patients with stable angina and a positive exercise test (1mm ST depression) from the Total Ischaemic Burden European Trial (TIBET) study, were studied. Resting ECG, exercise tolerance testing and echocardiography were performed at baseline, off anti-anginal therapy. The patients were then randomised to treatment with atenolol, nifedipine or a combination of both. Clinical follow up continued for an average of 2 years (range 1-3 years). RESULTS AND CONCLUSIONS: Prior MI or prior CABG were the clinical parameters associated with adverse outcome in patients with stable angina and a positive exercise test. On the ECG, left ventricular hypertrophy was predictive, and on echocardiogram, increased left ventricular dimensions were predictive of adverse events. When combined with time to ischaemia on exercise testing in a simple clinically applicable table these factors could be used to predict of 2 year probability of events for an individual patient.
Asunto(s)
Angina de Pecho/complicaciones , Adulto , Anciano , Anciano de 80 o más Años , Angina de Pecho/tratamiento farmacológico , Angina Inestable/complicaciones , Angina Inestable/diagnóstico , Muerte Súbita Cardíaca/etiología , Ecocardiografía/métodos , Electrocardiografía/métodos , Prueba de Esfuerzo/métodos , Tolerancia al Ejercicio , Femenino , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Análisis Multivariante , Infarto del Miocardio/diagnóstico , Infarto del Miocardio/etiología , Valor Predictivo de las Pruebas , Pronóstico , Disfunción Ventricular Izquierda/diagnóstico , Disfunción Ventricular Izquierda/etiologíaRESUMEN
1. The relative potencies of amiloride (5 and 20 mg) and spironolactone (25 and 100 mg) for plasma and erythrocyte electrolytes were investigated in a double-blind, randomised, balanced, crossover study in 12 normal men treated concomitantly with hydrochlorothiazide 100 mg daily for 1 week. 2. Participants satisfied an a priori requirement for a fall in plasma potassium concentration of at least 0.5 mmol l-1 after 7 days of treatment with hydrochlorothiazide alone. 3. After hydrochlorothiazide alone, plasma potassium and sodium concentrations fell (P < 0.001). There were associated reductions in erythrocyte sodium (P < 0.01). Plasma magnesium concentration did not change, although erythrocyte magnesium decreased (P < 0.001). 4. Both amiloride and spironolactone attenuated the thiazide-induced fall in plasma potassium (relative potency, amiloride:spironolactone 10:1, 95% confidence interval 6.3-16.2:1). Amiloride but not spironolactone was associated with a dose-related increase in plasma magnesium; a relative potency estimation was precluded. There was little evidence of influences of amiloride or spironolactone on erythrocyte electrolytes. 5. On a weight basis, amiloride is ten times more potent than spironolactone as a potassium-sparing agent in diuretic-treated subjects but neither agent had major effects on erythrocyte potassium. The drugs may have divergent actions on magnesium handling; hydrochlorothiazide alone had no influence on plasma magnesium.
Asunto(s)
Amilorida/farmacología , Hidroclorotiazida/farmacología , Magnesio/sangre , Potasio/sangre , Espironolactona/farmacología , Adulto , Aldosterona/sangre , Amilorida/efectos adversos , Amilorida/sangre , Método Doble Ciego , Interacciones Farmacológicas , Eritrocitos/química , Humanos , Hidroclorotiazida/efectos adversos , Líquido Intracelular/metabolismo , Masculino , Espironolactona/efectos adversos , Espironolactona/sangreRESUMEN
The anti-anginal properties of single doses of a new anti-hypertensive drug, cicletanine, were investigated in a double-blind, randomised, balanced, crossover comparison with placebo in sixteen patients with chronic stable angina pectoris. All subjects underwent treadmill exercise 2 h after drug administration and 24 h ambulatory ECG monitoring with ST scanning. Although there were significantly fewer episodes of ST depression on ambulatory monitoring after cicletanine, total exercise duration and time to 1 mm ST depression were unchanged. This report provides little evidence of an acute anti-anginal effect of cicletanine but longer term studies may be indicated to further evaluate this drug's potential role in the management of angina pectoris.
Asunto(s)
Angina de Pecho/tratamiento farmacológico , Piridinas/uso terapéutico , Adulto , Anciano , Angina de Pecho/fisiopatología , Método Doble Ciego , Electrocardiografía/efectos de los fármacos , Tolerancia al Ejercicio/efectos de los fármacos , Femenino , Hemodinámica/efectos de los fármacos , Humanos , Masculino , Persona de Mediana EdadRESUMEN
1. Potential pharmacodynamic and pharmacokinetic interactions between verapamil and propranolol were evaluated in two double-blind, randomised, balanced, crossover studies employing the same six healthy males. 2. The first study examined the effect of repeated propranolol administration on the pharmacodynamics and pharmacokinetics of verapamil after single oral and intravenous doses. The second explored the pharmacodynamics and pharmacokinetics of verapamil and propranolol alone and in combination after single and repeated oral doses. 3. The magnitude of the prolongation of PR interval induced by oral and intravenous verapamil was not affected by pre-treatment with propranolol. When verapamil and propranolol were co-administered as single doses, effects on PR interval were additive but, following repeated doses, a trend towards greater than additive prolongation was seen. The arithmetic sum of the effects of the two drugs was 23% (95% C.I. 8-38%) but the measured increase after the combination was 40% (95% C.I. 26-54%). 4. The extent of reduction in heart rate and blood pressure at rest and after exercise following repeated doses of propranolol was not influenced by single oral or intravenous doses of verapamil. The heart rate and blood pressure responses to single and repeated oral doses of verapamil and propranolol in combination were significantly greater than those after either drug alone and approximated to the arithmetic sum of the individual responses. 5. Although repeated administration of propranolol reduced hepatic blood flow as assessed by indocyanine green clearance, there was no evidence of an interaction between the drugs at this level. 6. The pharmacokinetics of verapamil and norverapamil were not significantly affected by prior propranolol. After single doses of verapamil and propranolol in combination, the maximum plasma concentration of propranolol was increased and the oral clearance of verapamil reduced. No pharmacokinetic interaction was observed after repeated doses. 7. These findings provide little evidence of a pharmacodynamic or pharmacokinetic interaction between verapamil and propranolol in normal subjects. Most of the haemodynamic responses to these drugs in combination can be explained by additive drug effects but an interaction affecting AV conduction after repeated doses cannot be excluded. The minor pharmacokinetic interaction between the drugs is unlikely to be relevant to the pharmacodynamic changes.
Asunto(s)
Propranolol/farmacología , Verapamilo/farmacología , Adulto , Presión Sanguínea/efectos de los fármacos , Método Doble Ciego , Interacciones Farmacológicas , Ejercicio Físico , Frecuencia Cardíaca/efectos de los fármacos , Hemodinámica/efectos de los fármacos , Humanos , Verde de Indocianina , Circulación Hepática/efectos de los fármacos , Masculino , Propranolol/farmacocinética , Distribución Aleatoria , Renina/sangre , Verapamilo/farmacocinéticaRESUMEN
Twice-daily captopril (25 mg) and placebo were compared in ten hypertensive patients who were already receiving bendrofluazide. After six weeks therapy, captopril produced significant antihypertensive effects one to six hours after dosing but these did not persist at eleven to twelve hours. Plasma renin concentration was increased for twelve hours after captopril but inhibition of angiotensin II activity was lost by twelve hours. During the period when captopril reduced blood pressure significantly, effective renal plasma flow and hepatic blood flow were unchanged although renal vascular resistance was reduced. There was no evidence that captopril altered plasma sodium, potassium or magnesium concentrations following bendrofluazide. Thus, in thiazide-treated patients, captopril 25 mg produces significant blood pressure reduction for at least six hours after dosing, without impairing renal or hepatic blood flow. However, twice-daily low-dose captopril does not adequately control blood pressure throughout the dosage interval.
Asunto(s)
Benzotiadiazinas , Captopril/administración & dosificación , Hipertensión/tratamiento farmacológico , Inhibidores de los Simportadores del Cloruro de Sodio/farmacología , Adulto , Anciano , Angiotensina II/sangre , Captopril/efectos adversos , Captopril/farmacología , Diuréticos , Evaluación de Medicamentos , Quimioterapia Combinada , Femenino , Hemodinámica/efectos de los fármacos , Humanos , Masculino , Persona de Mediana Edad , Renina/sangre , Sodio/sangre , Inhibidores de los Simportadores del Cloruro de Sodio/administración & dosificaciónRESUMEN
Reports of increased numbers of IgE-containing plasma cells in rectal biopsy specimens from patients with ulcerative colitis and non-specific proctitis have not been confirmed by others. All of these studies used conventional anti-IgE sera in immunocytochemical techniques and it is possible that the discrepancies are due to a lack of specificity of some of these reagents. A monoclonal antibody specific for human IgE was applied in this study of 23 patients. Positively stained cells were rarely found in the biopsy specimens of both the disease and normal control groups.